US Patent

US10537554 — Pharmaceutical composition for treating migraine

Method of Use · Assigned to Upsher Smith Laboratories LLC · Expires 2036-01-29 · 10y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of treating migraine or cluster headache in a human patient by administering 3 mg of subcutaneous sumatriptan or its salt.

USPTO Abstract

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-72`	—	sumatriptan-succinate

Patent Metadata

Patent number: US10537554
Jurisdiction: US
Classification: Method of Use
Expires: 2036-01-29
Drug substance claim: No
Drug product claim: No
Assignee: Upsher Smith Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.